Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xuezhita
- Development stage
- Unknown
- Lead developer
- Changsha Innovative Traditional Chinese Medicine Modernization Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xuezhita is a Traditional Chinese Medicine (TCM) candidate developed by the Changsha Innovative Traditional Chinese Medicine Modernization Research Institute for the treatment of hyperlipidemia. It is a purified extract derived from the rhizome of *Alisma orientale* (Ze Xie), standardized for its active triterpene constituents, such as alisol A and alisol B. The drug primarily functions by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis, and may also modulate cholesterol absorption through the inhibition of sterol O-acyltransferase (ACAT). Clinical studies in China have indicated that Xuezhita effectively reduces serum levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) while maintaining or increasing high-density lipoprotein cholesterol (HDL-C) levels. It has been advanced through Phase III clinical trials and received a National Class 2 New Drug Certificate in China.
- Brand names
- Xuezhita
- Other names
- Xuezhita CapsulesAlisma orientale extract
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on xuezhita.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xuezhita.